WOODBRIDGE,
ON, May 7, 2014 /PRNewswire/ -
Pivotal Therapeutics Inc. (OTCQX: PVTTF) (CSE: PVO), a
specialty pharmaceutical company with a focus on Omega-3 therapies
for cardiovascular disease (CVD) and overall health, announced
today that the U.S. Patent and Trademark Office (USPTO) has issued
Patent Number 8,715,648 titled "Formulations Comprising Omega-3
Fatty Acids and Anti-Obesity Agent for the Reduction of Body Weight
in Cardiovascular Disease Patients (CVD) and Diabetics". This
patent covers Pivotal's unique formulation in conjunction with
anti-obesity agents for the reduction of body weight in CVD
patients and diabetics. This patent has terms that expire no
earlier than 2031.
"This patent issuance represents an important
step in further protecting and advancing the commercial potential
of VASCAZEN®'s formulation," said Dr.
George Jackowski, Chairman and Chief
Scientific Officer "Our unique 6:1 EPA:DHA formulation when used in
combination with anti-obesity drugs may play a positive role in
addressing Obesity," added Dr. Jackowski.
This issued patent is the first of seven patent
applications currently in prosecution in the United States. Pivotal is pursuing patent
applications related to its formulation, composition and
combinations with existing cardiovascular drugs in the U.S. and
multiple jurisdictions outside the United
States.
About VASCAZEN®
VASCAZEN® is currently
available in the U.S. as a prescription only medical food
specifically formulated for the dietary management of an Omega-3
deficiency in cardiovascular patients. VASCAZEN®
is a >90% pure Omega-3 with a proprietary 6:1 EPA:DHA fatty acid
formulation, protected by a series of both U.S. and foreign
patents.
VASCAZEN® has been clinically
shown to correct an Omega-3 deficiency within eight weeks of
treatment with positive concomitant effects on the lipid profiles,
mainly a 48% reduction of triglycerides and an increase of HDL
without negative impact on the LDL-C lipid profile.
VASCAZEN®'s results were achieved with a
dose of 3 grams of EPA and DHA per day of a prescription grade,
high purity Omega-3.
About Pivotal Therapeutics Inc.
Pivotal Therapeutics is a publicly traded (OTCQX:
PVTTF) (CSE: PVO) specialty pharmaceutical company with a focus on
cardiovascular disease and overall health. Pivotal Therapeutics'
lead product VASCAZEN® is a prescription only
medical food formulated to meet the dietary Omega-3 deficient needs
of patients with cardiovascular disease through elevating
Eicosapentaenoic acid (EPA) and Docosahexaenoic acid (DHA) to
levels associated with reduced risk of cardiovascular
complications. OMAZEN® is a pharmaceutical grade
Omega-3 providing over 90% pure Omega-3 in each capsule for the
maintenance of good health. OMAZEN® is a patented
product available for sale and distribution in Canada
Disclosure Notice
The information
contained in this document is as of May 7,
2014. This press release contains forward-looking
statements. Such forward-looking statements are subject to a number
of risks, assumptions and uncertainties that could cause Pivotal's
actual results to differ materially from those projected in such
forward-looking statements. These statements can be identified by
the use of words such as "will", "anticipate", "estimate",
"expect", "project", "forecast", "intend", "plan", "believe",
"project", "potential", and similar expressions with any discussion
of future operating or financial performance or events. In
particular, factors that could cause actual results to differ
materially from those in forward looking statements include the
following: Pivotal's inability to obtain additional financing on
acceptable terms; growth in costs and expenses; inability to
compete with others who provide comparable products; risk that the
Company's products will not gain widespread market acceptance;
risks relating to the Company's ability to maintain its CSE
listing. Forward-looking statements speak only as of the date made
and are not guarantees of future performance. The Company
undertakes no obligation to publicly update or revise any
forward-looking statements contained in this document as a result
of new information or future events or developments. CSE has not
reviewed and does not accept responsibility for the adequacy or
accuracy of this information.
SOURCE Pivotal Therapeutics Inc.